GSK’s (GSK) “Buy” Rating Reiterated at Citigroup

Citigroup restated their buy rating on shares of GSK (LON:GSK) in a research note released on Tuesday, Marketbeat.com reports. They currently have a GBX 1,900 target price on the stock.

Several other research firms have also recently issued reports on GSK. Deutsche Bank Aktiengesellschaft upped their price target on GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Finally, Berenberg Bank raised their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,839.29.

GSK Stock Performance

LON:GSK opened at GBX 1,812 on Tuesday. The company has a 50-day moving average of GBX 1,821.44 and a 200-day moving average of GBX 1,641.33. The firm has a market cap of £73.10 billion, a price-to-earnings ratio of 13.62, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 1,909.73.

GSK (LON:GSK) last released its earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In related news, insider Jonathan Symonds purchased 1,650 shares of the stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker acquired 441 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average price of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.